481 related articles for article (PubMed ID: 20395444)
1. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
Khramtsov AI; Khramtsova GF; Tretiakova M; Huo D; Olopade OI; Goss KH
Am J Pathol; 2010 Jun; 176(6):2911-20. PubMed ID: 20395444
[TBL] [Abstract][Full Text] [Related]
2. Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.
Khalil S; Tan GA; Giri DD; Zhou XK; Howe LR
PLoS One; 2012; 7(3):e33421. PubMed ID: 22457761
[TBL] [Abstract][Full Text] [Related]
3. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
Geyer FC; Lacroix-Triki M; Savage K; Arnedos M; Lambros MB; MacKay A; Natrajan R; Reis-Filho JS
Mod Pathol; 2011 Feb; 24(2):209-31. PubMed ID: 21076461
[TBL] [Abstract][Full Text] [Related]
4. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
[TBL] [Abstract][Full Text] [Related]
5. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
6. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
Prasad CP; Gupta SD; Rath G; Ralhan R
Oncology; 2007; 73(1-2):112-7. PubMed ID: 18337623
[TBL] [Abstract][Full Text] [Related]
7. WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer.
Wend P; Runke S; Wend K; Anchondo B; Yesayan M; Jardon M; Hardie N; Loddenkemper C; Ulasov I; Lesniak MS; Wolsky R; Bentolila LA; Grant SG; Elashoff D; Lehr S; Latimer JJ; Bose S; Sattar H; Krum SA; Miranda-Carboni GA
EMBO Mol Med; 2013 Feb; 5(2):264-79. PubMed ID: 23307470
[TBL] [Abstract][Full Text] [Related]
8. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
[TBL] [Abstract][Full Text] [Related]
9. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.
Prosperi JR; Goss KH
Curr Drug Targets; 2010 Sep; 11(9):1074-88. PubMed ID: 20545611
[TBL] [Abstract][Full Text] [Related]
10. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast.
Prasad CP; Mirza S; Sharma G; Prashad R; DattaGupta S; Rath G; Ralhan R
Life Sci; 2008 Aug; 83(9-10):318-25. PubMed ID: 18662704
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
López-Knowles E; Zardawi SJ; McNeil CM; Millar EK; Crea P; Musgrove EA; Sutherland RL; O'Toole SA
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):301-9. PubMed ID: 20056651
[TBL] [Abstract][Full Text] [Related]
13. β-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis.
Klemm F; Bleckmann A; Siam L; Chuang HN; Rietkötter E; Behme D; Schulz M; Schaffrinski M; Schindler S; Trümper L; Kramer F; Beissbarth T; Stadelmann C; Binder C; Pukrop T
Carcinogenesis; 2011 Mar; 32(3):434-42. PubMed ID: 21173432
[TBL] [Abstract][Full Text] [Related]
14. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.
Bhardwaj A; Ganesan N; Tachibana K; Rajapakshe K; Albarracin CT; Gunaratne PH; Coarfa C; Bedrosian I
PLoS One; 2015; 10(5):e0127678. PubMed ID: 26000884
[TBL] [Abstract][Full Text] [Related]
15. LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
Hou MF; Chen PM; Chu PY
BMC Cancer; 2018 Feb; 18(1):219. PubMed ID: 29471794
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer.
Tan Z; Zheng H; Liu X; Zhang W; Zhu J; Wu G; Cao L; Song J; Wu S; Song L; Li J
Oncotarget; 2016 Apr; 7(17):24076-87. PubMed ID: 26992223
[TBL] [Abstract][Full Text] [Related]
17. Role of regulatory miRNAs of the Wnt/ β-catenin signaling pathway in tumorigenesis of breast cancer.
Rahmani F; Tadayyon Tabrizi A; Hashemian P; Alijannejad S; Rahdar HA; Ferns GA; Hassanian SM; Shahidsales S; Avan A
Gene; 2020 Sep; 754():144892. PubMed ID: 32534060
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
20. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
